Cancer Immunotherapy Market Research Report by Function, Product, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

The Global Cancer Immunotherapy Market size was estimated at USD 66.14 billion in 2021 and expected to reach USD 69.63 billion in 2022, and is projected to grow at a CAGR 5.44% to reach USD 90.92 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Cancer Immunotherapy to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Function, the market was studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer.

Based on Product, the market was studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. The Cell Therapies is further studied across Chimeric Antigen Receptor T Cell Therapy and Dendritic Cells. The Checkpoint Inhibitors is further studied across Cytotoxic T-Lymphocyte-Associated Protein-4 and Programmed Death 1 & Programmed Death Ligand 1. The Immunomodulators is further studied across Granulocyte-Macrophage Colony-Stimulating Factor, Interferons, Interleukins, and Oncolytic Virus. The Monoclonal Antibodies is further studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Naked Monoclonal Antibodies. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines.

Based on End User, the market was studied across Cancer Research Institutes, Clinics, and Hospitals.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer Immunotherapy market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Immunotherapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Immunotherapy Market, including Amgen Inc., Amneal Pharmaceutical Inc., Apotex Inc, Astrazeneca, Avid Bioservices, Inc., Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Dr. Reddy’s Laboratories Ltd, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GlaxoSmithKline Plc, Gristone Oncology, Inc., Hikma Pharmaceutical PLC, Immunomedics Inc, Janssen Global Services, LLC, Lupin Limited, Merck & Co., Inc., Mylan N.V., Novartis International AG, OSE Immunotherapeutics SA, Pfizer, Inc., Seagen Inc, Spectrum Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Cancer Immunotherapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Immunotherapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Immunotherapy Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Immunotherapy Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Immunotherapy Market?
6. What is the market share of the leading vendors in the Global Cancer Immunotherapy Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Immunotherapy Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer patients worldwide
5.1.1.2. Increasing adoption of advanced cancer therapeutics
5.1.1.3. Surging investments in research and development activities of cancer treatment
5.1.2. Restraints
5.1.2.1. Capital intensive treatment and procedures
5.1.3. Opportunities
5.1.3.1. Extensive development of bioinformatics tools in drug development process
5.1.3.2. Growing number of clinical trials for cancer immunotherapy
5.1.4. Challenges
5.1.4.1. Complications in cancer limiting the immune response
5.2. Cumulative Impact of COVID-19

6. Cancer Immunotherapy Market, by Function
6.1. Introduction
6.2. Breast Cancer
6.3. Colorectal Cancer
6.4. Head & Neck Cancer
6.5. Lung Cancer
6.6. Melanoma
6.7. Multiple Myeloma
6.8. Prostate Cancer

7. Cancer Immunotherapy Market, by Product
7.1. Introduction
7.2. Cell Therapies
7.3.1. Chimeric Antigen Receptor T Cell Therapy
7.3.2. Dendritic Cells
7.3. Checkpoint Inhibitors
7.4.1. Cytotoxic T-Lymphocyte-Associated Protein-4
7.4.2. Programmed Death 1 & Programmed Death Ligand 1
7.4. Immunomodulators
7.5.1. Granulocyte-Macrophage Colony-Stimulating Factor
7.5.2. Interferons
7.5.3. Interleukins
7.5.4. Oncolytic Virus
7.5. Monoclonal Antibodies
7.6.1. Bispecific Monoclonal Antibodies
7.6.2. Conjugated Monoclonal Antibodies
7.6.3. Naked Monoclonal Antibodies
7.6. Vaccines
7.7.1. Prophylactic Vaccines
7.7.2. Therapeutic Vaccines

8. Cancer Immunotherapy Market, by End User
8.1. Introduction
8.2. Cancer Research Institutes
8.3. Clinics
8.4. Hospitals

9. Americas Cancer Immunotherapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Cancer Immunotherapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Amgen Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Amneal Pharmaceutical Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Apotex Inc
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Astrazeneca
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Avid Bioservices, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bausch Health Companies Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bayer AG
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Bristol-Myers Squibb
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. C.H. Boehringer Sohn AG & Ko. KG
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Celgene Corporation
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Dr. Reddy’s Laboratories Ltd
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. ELI Lilly and Company
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. F. Hoffmann-La Roche Ltd
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Fresenius Kabi AG
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. GlaxoSmithKline Plc
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Gristone Oncology, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Hikma Pharmaceutical PLC
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Immunomedics Inc
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Janssen Global Services, LLC
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Lupin Limited
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Merck & Co., Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Mylan N.V.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Novartis International AG
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. OSE Immunotherapeutics SA
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Pfizer, Inc.
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Seagen Inc
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Spectrum Pharmaceuticals, Inc.
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
13.28. Sun Pharmaceutical Industries Ltd
13.28.1. Business Overview
13.28.2. Key Executives
13.28.3. Product & Services
13.29. Teva Pharmaceutical Industries Ltd
13.29.1. Business Overview
13.29.2. Key Executives
13.29.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing